The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.
Research output: Contribution to journal › Journal article › peer-review
Glucagon-like peptide-1 (GLP-1), a future treatment for type 2 diabetes, is efficiently degraded by the enzyme dipeptidyl peptidase IV (DPP IV), yielding the major metabolite GLP-1-(9-36)-amide. In this study, we examined the potential glucose lowering effect of GLP-1-(9-36)-amide in mice and found that GLP-1-(9-36)-amide (3 and 10 nmol/kg) did not affect insulin secretion or glucose elimination when administered intravenously together with glucose (1 g/kg). This was observed both in normal mice and in transgenic mice having a complete disruption of the signalling from the GLP-1 receptor. Furthermore, after blocking insulin secretion, using diazoxide (25 mg/kg), no effect on insulin-independent glucose disposal of GLP-1-(9-36)-amide was observed. Therefore, GLP-1-(9-36)-amide does not affect glucose disposal in mice either in the presence or absence of intact GLP-1-receptors or in the presence or absence of stimulated insulin levels. This suggests that the GLP-1 metabolite is not involved in the regulation of glucose homeostasis.
Original language | English |
---|---|
Journal | European Journal of Pharmacology |
Volume | 494 |
Issue number | 2-3 |
Pages (from-to) | 283-8 |
Number of pages | 5 |
ISSN | 0014-2999 |
DOIs | |
Publication status | Published - 2004 |
Bibliographical note
Keywords: Animals; Blood Glucose; Diazoxide; Female; Glucagon-Like Peptide 1; Hypoglycemic Agents; Injections, Intravenous; Insulin; Islets of Langerhans; Mice; Mice, Transgenic; Peptides; Potassium Channels; Receptors, Glucagon
ID: 8417367